Eagle Asset Management Inc. lowered its stake in Emergent Biosolutions, Inc. (NYSE:EBS) by 2.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 237,371 shares of the biopharmaceutical company’s stock after selling 6,459 shares during the period. Eagle Asset Management Inc. owned 0.58% of Emergent Biosolutions worth $6,893,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. State of Alaska Department of Revenue increased its stake in shares of Emergent Biosolutions by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 100 shares during the period. Elkfork Partners LLC bought a new stake in shares of Emergent Biosolutions during the fourth quarter valued at approximately $132,000. Envestnet Asset Management Inc. increased its stake in shares of Emergent Biosolutions by 29.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 4,866 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 1,110 shares during the period. Pacad Investment Ltd. bought a new stake in shares of Emergent Biosolutions during the fourth quarter valued at approximately $194,000. Finally, Trexquant Investment LP bought a new stake in shares of Emergent Biosolutions during the fourth quarter valued at approximately $201,000. 85.92% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions, Inc. (EBS) traded up 3.96% during mid-day trading on Wednesday, reaching $33.58. 226,721 shares of the company traded hands. Emergent Biosolutions, Inc. has a 12-month low of $24.47 and a 12-month high of $39.21. The company’s 50-day moving average is $31.21 and its 200-day moving average is $30.72. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of 26.69 and a beta of 1.22.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.31 by $0.08. The firm had revenue of $116.90 million during the quarter, compared to analysts’ expectations of $121.30 million. Emergent Biosolutions had a return on equity of 11.92% and a net margin of 10.36%. Emergent Biosolutions’s revenue for the quarter was up 13.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.16 earnings per share. Equities analysts predict that Emergent Biosolutions, Inc. will post $1.58 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Eagle Asset Management Inc. Sells 6,459 Shares of Emergent Biosolutions, Inc. (EBS)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/06/21/emergent-biosolutions-inc-ebs-position-cut-by-eagle-asset-management-inc-updated-updated-updated-updated.html.

Separately, Zacks Investment Research raised shares of Emergent Biosolutions from a “sell” rating to a “hold” rating in a research report on Tuesday, February 21st. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $39.40.

In related news, EVP Adam Havey sold 11,419 shares of the company’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $28.62, for a total value of $326,811.78. Following the sale, the executive vice president now directly owns 26,046 shares of the company’s stock, valued at $745,436.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 16.50% of the stock is owned by corporate insiders.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.